Two Sigma Advisers LP decreased its position in Cerus Co. (NASDAQ:CERS) by 21.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 343,700 shares of the biotechnology company’s stock after selling 91,600 shares during the period. Two Sigma Advisers LP’s holdings in Cerus were worth $1,743,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Raymond James Trust N.A. bought a new position in Cerus in the fourth quarter worth approximately $71,000. Shufro Rose & Co. LLC raised its stake in Cerus by 13.3% in the fourth quarter. Shufro Rose & Co. LLC now owns 17,000 shares of the biotechnology company’s stock worth $86,000 after buying an additional 2,000 shares in the last quarter. Great West Life Assurance Co. Can raised its stake in Cerus by 141.8% in the fourth quarter. Great West Life Assurance Co. Can now owns 19,824 shares of the biotechnology company’s stock worth $97,000 after buying an additional 11,624 shares in the last quarter. Mackenzie Financial Corp bought a new position in Cerus in the third quarter worth approximately $119,000. Finally, United Services Automobile Association raised its stake in Cerus by 7.5% in the fourth quarter. United Services Automobile Association now owns 33,524 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,344 shares in the last quarter. Hedge funds and other institutional investors own 66.38% of the company’s stock.

Shares of CERS stock opened at $6.54 on Wednesday. The firm has a market cap of $903.87 million, a PE ratio of -14.86 and a beta of 1.43. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.53 and a current ratio of 2.79. Cerus Co. has a 12-month low of $4.70 and a 12-month high of $8.05.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The business had revenue of $16.50 million for the quarter, compared to analyst estimates of $18.74 million. Cerus had a negative return on equity of 65.35% and a negative net margin of 84.15%. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.10) earnings per share. On average, analysts predict that Cerus Co. will post -0.42 earnings per share for the current year.

In related news, CEO William Mariner Greenman sold 7,781 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $6.48, for a total value of $50,420.88. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Kevin Dennis Green sold 23,524 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $2.05, for a total value of $48,224.20. Following the completion of the transaction, the chief financial officer now directly owns 66,825 shares in the company, valued at $136,991.25. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 57,647 shares of company stock worth $254,880. Insiders own 6.80% of the company’s stock.

A number of equities analysts recently commented on the stock. BidaskClub downgraded shares of Cerus from a “buy” rating to a “hold” rating in a research note on Friday, March 1st. Zacks Investment Research downgraded Cerus from a “buy” rating to a “hold” rating in a research report on Monday, March 4th. Finally, ValuEngine downgraded Cerus from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 22nd. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Cerus currently has a consensus rating of “Buy” and an average target price of $8.50.

WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/two-sigma-advisers-lp-lowers-position-in-cerus-co-cers/2952430.html.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Further Reading: Asset Allocation Models, Which is Right For You?

Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERS).

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.